Effectiveness of First-line Natalizumab Treatment in Patients with Highly Active Relapsing-remitting Multiple Sclerosis
Su-Hyun Kim, MD, PhD, Ho Jin Kim, MD, PhD
Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea
Patients with highly active relapsing-remitting multiple sclerosis (RRMS) may benefit from early aggressive
therapy instead of the escalation approach. Here we describe the outcome of a patient with
highly active RRMS (two relapses in the year after onset and a few gadolinium-enhancing lesions on
brain MRI) treated with natalizumab as a first-line treatment. Over 2 years of natalizumab treatment,
no evidence of disease activity was observed. An early aggressive approach may improve treatment
outcome in patients with highly active RRMS.
Journal of Multiple Sclerosis 9(2):21-23, 2018
